
ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-

An Exciting New Clinical Trial for Those who Are Resistant to ALK Inhibitors Is Recruiting Soon
Those in the ALK community fear the day when progression occurs after Lorlatinib, the “last” ALK inhibitor available. Although there are effective treatments after Lorlatinib, there is no standard treatment.
-

What is YAP and its significance for ALK-positive cancer
In recent years, a signal pathway called HIPPO, which is important in angiogenesis (blood vessel growth), has become important for the ALK cancer realm. There has been accumulating evidence that
-

Revival of Cancer Moonshot initiative announced by President Biden
In February 2022, President Biden announced and laid out an ambitious agenda to boost and speed up the fight against cancer, including a national year of action on cancer screening and
-

An Interview with Dr. Alice Shaw at ALKtALK, Feb. 2022
Dr. Alice Shaw, MD, PhD, Boston, MA Global Head of Translational Clinical Oncology at Novartis Attending physician, Center for Thoracic Cancers at Massachussets General Hospital Associate Professor of medicine at
-
LUNGevity Partners with ALK Positive to Award $1.5 Million in Lung Cancer Research Grants
FOR IMMEDIATE RELEASEMedia ContactColin Bartonmedical@alkpositive.org303-204-3388 WASHINGTON, DC (January 27, 2022) — LUNGevity Foundation is partnering for the third time with the patient-led registered nonprofit organization ALK Positive to support the
-
$7.6M Gift Launches New Lung Cancer Research Initiative at University of Michigan’s Rogel Cancer Center
EDITOR’S NOTE: This is a reprint of a press release from the University of Michigan’s Rogel Cancer Center – this $7.6 million gift from Judith L. Tam and the Richard
-
Understanding ALK structural data
“Know thy self, know thy enemy. A thousand battles, a thousand victories”; a quote by the famous Chinese historical figure Sun Tzu. Accordingly, scientists have been working hard at understanding the
-

Clinical Trials Can Help Those with ALK Lung Cancer Get State of the Art Treatment
In this newsletter, we pay tribute to Linnea Olson, a 17-year ALK-positive lung cancer survivor. We lost her in November of 2021, but her legacy as a creative, kind, and

